A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Arimoclomol (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ORARIALS-01
- Sponsors Orphazyme
- 02 Nov 2018 According to a CytRx corporation media release, in September 2018, CytRx announced receipt of a milestone payment totaling $250,000 (USD) from Orphazyme, as a result of dosing the first patient in this study.
- 16 Aug 2018 Planned End Date changed from 14 Jan 2021 to 1 Jan 2021.
- 16 Aug 2018 Planned primary completion date changed from 31 Dec 2020 to 1 Dec 2020.